SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS

September 1, 2022

SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS

SOMERSET, NJ — Solco Healthcare is proud to announce the FDA approval on April 7, 2022 and September 2022 availability of Nebivolol tablets, 2.5mg, 5mg, 10mg and 20mg an AB-rated equivalent to Bystolic® by Allergan, Inc.

Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure and may be used alone or in combination with other antihypertensive agents. According to IQVIA, total generic market sales for Nebivolol tablets for the last twelve months ending August 2022 were $56.3 million.

Solco Healthcare is marketing Nebivolol tablets, 2.5mg in 30 count bottles and the 5mg, 10mg and 20mg strengths in 30 and 90 count bottles. Please contact your Solco Healthcare National Accounts Director or customer service at (855) 581-9688 for more information.